

Sterne, Kessler, Goldstein & Fox P.L.L.C.

ATTORNEYS AT LAW

HOO NEW YORK AVENUE, N.W. . WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 . FACSIMILE: (202) 371-2540 . www.skgf.com

DUPLICATE

ROBERT GREENE STERNE EDWARD J. KESSLER JORGE A. GOLDSTEIN SAMUEL L. FOX*** DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G. DURKIN MICHELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE MICHAEL O. LEE STEVEN R. LUDWIG

JOHN M. COVERT LINDA E. ALCORN ROBERT C. MILLONIG MICHAEL V. MESSINGER JUDITH U. KIM TIMOTHY J. SHEA, JR. PATRICK E. GARRETT JEFFREY T. HELVEY* HEIDI L. KRAUS JEFFREY R. KURIN PATRICK D. O'BRIEN LAWRENCE B. BUGAISKY CRYSTAL D. SAYLES

EDWARD W. YEE ALBERT L. FERRO* DONALD R. BANOWIT PETER A. JACKMAN MOLLY A. MCCALL TERESA U. MEDLER JEFFREY S. WEAVER KENDRICK P. PATTERSON DONALD J. FEATHERSTONE VINCENT L. CAPUANO JOHN A. HARROUN* ALBERT J. FASULO III* ELDORA ELLISON FLOYD

December 3, 2001

W. RUSSELL SWINDELL THOMAS C. FIALA BRIAN J. DEL BUONO* VIRGIL L. BEASTON* RYAN J. STAMPER* REGINALD D. LUCAS* THEODORE A. WOOD ELIZABETH J. HAANES BRUCE E. CHALKER JOSEPH S. OSTROFF KAREN R. MARKOWICZ** SUZANNE E. ZISKA** ANDREA J. KAMAGE**

NANCY J. LEITH**
JOSEPH M. CONRAD, III** DOUGLAS M. WILSON* ANN E. SUMMERFIELD** CYNTHIA M. BOUCHEZ** HELENE C. CARLSON** GABY L. LONGSWORTH* DUSTIN T. JOHNSON **
MATTHEW J. DOWD ** AARON L. SCHWARTZ**

LIMITED TO MATTERS AND PROCEEDINGS BEFORE FEDERAL COURTS & AGENCIES REGISTERED PATENT AGENT ***SENIOR COUNSEL

Commissioner for Patents

Washington, D.C. 20231

WRITER'S DIRECT NUMBER: (202) 371-2589 **INTERNET ADDRESS:** LARRYB@SKGF.COM

ART UNIT 1648

Re: U.S. Patent Application

Appl. No. 09/482,682; Filed: January 14, 2000

Adenovirus Vectors, Packaging Cell Lines, Compositions, and

Methods for Preparation and Use

Inventors: Von Seggern et al.

Our Ref: 1294.0010001/RWE/LBB

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. SKGF Cover Letter (in duplicate);
- 2. Fee Transmittal (in duplicate):
- 3. Information Disclosure Statement;
- 4. Form PTO-1449 with cited 126 documents;
- 5. SKG&F Check No. 2325 in the amount of \$180.00 for fee under 37 C.F.R. § 1.71(p); and
- 6. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents December 3, 2001 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Lawrence B. Bugaisky

Attorney for Applicants

Registration No. 35,086

LBB/ybh

Enclosures

P:\USERS\YHARRIS\LBB\PTO\129411skgf.tr4


SKGF Rev. 11/01/01 mac

Reduction Act of 1995, no persons are required to perpond to a coll Under the Pape **EEE TRANSMITTAL**

for FY 2002

atent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$)180.00



METHOD OF PAYMENT (check one)			\$ P			FEE	CALCULATION (co	ontinued)			
				ITIONAL I Entity		Entity					
Deposit Account Number	19-0036	j .	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee De	Fee Description			
Deposit Account Name	Sterne, F	Kessler, Goldstein & Fox P.L.L.C.	105	130	205	65	Surcharge - late filing fee or oath				
Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17			127	50	227	25	Surcharge - late provisional	filing fee or cover sheet	[,
			139	130	139	130	Non-English specific	ation			
Applicant claims small entity status			147	2,520	147	2,520	For filing a request for	ex parte reexamina	ation		
See 37 CFR 1.27			112	920*	112	920*	Requesting publication of action	SIR prior to Examiner	. [
2. ⊠Payment Enclosed:			113	1,840*	113	1,840*	Requesting publication of	SIR after Examiner ac	ction		
⊠ Check □ Credit card □ Money Order Other* *Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036.			115	110	215	55	Extension for reply with	hin first month	Ì		
FEE CALCULATION			116	400	216	200	Extension for reply with	hin second month	Ì		ĺ
1. BASIC FILING FEE			117	920	217	460	Extension for reply with	hin third month	Ì		ĺ
Large Entity Small Entity			118	1,440	218	720	Extension for reply with	hin fourth month	Ì		i
Fee Fee Fee	Fee	Fee Description Fee Paid	128	1,960	228	980	Extension for reply with	hin fifth month	ı	*****	ĺ
Code (\$) Cod 101 740 201		Utility filing fee	119	320	219	160	Notice of Appeal		.		l
106 330 206		Design filing fee	120	320	220	160	Filing a brief in suppor	t of an appeal	. I		l
107 510 207		Plant filing fee	121		221		•	Request for oral hearing			ĺ
108 740 208		Reissue filing fee	138		138		Petition to institute a public use proceeding				ĺ
114 160 214		Provisional filing fee	140	•	240	-					
		-	141		241		Petition to revive - unir		1		
SUBTOTAL (1) (\$)			142	1,280	242	640	Utility issue fee (or reis	ssue)	1		
	-		143	460	243	230	Design issue fee		1		
			144	620	244	310	Plant issue fee				
			122	130	122	130	Petitions to the Comm	issioner			
2. EXTRA CLAIM FEES Fee from			123	130	123	130	Petitions related to pro	ovisional application	ns		
Total Claims	- 20** =	Extra below Fee Paid : X =	126	180	126	180	Submission of Informa	ation Disclosure Str	nt	\$180.00	
		= X =	581	. 40	481	40	Recording each patent assignment per property (times number of properties)				
Multiple Dependent =			146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))				
Large Entity Sma Fee Fee Fee	Fee	Fee Description	149	740	249		For each additional invention to be examined (37 CFR 1.129(b))				
Code (\$) Cod 103 18 203		Claims in excess of 20	179	740	279	370	Request for Continued Examination (RCE)				
102 84 202	42	Independent claims in excess of 3	169	900	169	900	Request for expedited examination of a design			1	
104 280 204	140	Multiple dependent claim	Cibar for	· (====ifi) .			application				1
108 84 209		**Reissue independent claims over original patent	Other fee	e (specify) :							
110 18 210 9 **Reissue claims in excess of 20 and over original patent				e (specify) :	·):						
SUBTOTAL (2) (\$)				Reduced by Basic Filing Fee Paid							
	ly paid, if g	greater; For Reissues, see above		SUBTOTAL (3) (\$) 180.00							-
SUBMITTED BY							т і	Complete (if app	licable	'	_
Name (Print/Type		l R	Registration No.		35,086	Telephone	202-371-2600				



#1/ 12·15·01 · PP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VON SEGGERN et al.

Appl. No. 09/482,682

Filed: January 14, 2000

For:

Adenovirus Vectors, Packaging

Cell Lines, Compositions, and Methods for Preparation and Use

Art Unit: 1648

Examiner: Foley, S.

Atty. Docket: 1294.0010001/RWE/LBB

Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following concise explanation of relevance of the non-English language documents based on the English-language abstracts for Documents AM2, AM3, and AN3 cited on Form PTO 1449.

Document AM2, WO 96/22378, is believed to discuss adenovirus with mutations in the fibre protein to alter binding selectivity. An English-language abstract of Document AM3 is provided as Document AT35.

Document AN3, EP 0 892 047, is believed to discuss semaphorin L proteins - used as immunosuppressants and antiinflammatory agents in organ transplants, inflammation therapy, immunotherapy and gene therapy. An English-language abstract of Document AN3 is provided as Document AR36.

12/04/2001 HDEMESS1 00000055 09482682

01 FC:126

180.00 OP

Document AM3, WO 98/44121, is believed to discuss cells for production of recombinant adeno and adeno-associated viruses containing part of the E4 region of adeno virus, used to produce new adeno viruses defective in E1 and E4 regions for use as gene therapy vectors. An English-language abstract of Document AM2 is provided as Document AS35.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before

the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our Check No. 33359 in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Laurer B. Bugarish

Lawrence B. Bugaisky Attorney for Applicants

Registration No. 35,086

Date: December 3, 2007

1100 New York Avenue, N.W.

Suite 600

Washington, D.C. 20005-3934

(202) 371-2600

P:\USERS\YHARRIS\LBB\Pto\129411.ids SKGF Rev. 4/28/00 mac